Biotransformation in Drug Discovery and Development

- F. Wu, H. Li, Q. An, Y. Sun, J. Yu, W. Cao, P. Sun, X. Diao, L. Meng, S. Xu. Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. European journal of medicinal chemistry. 2023;254:115355.

- D. Rao, T. Yang, H. Feng, Q. An, S. Zhang, J. Yu, X. Ren, X. Diao, H. Huang, W. Tang, S. Xu. Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis. Journal of medicinal chemistry. 2023;66(17):12018-32.

- Y. Wu, L. Pan, Z. Chen, Y. Zheng, X. Diao, D. Zhong. Metabolite Identification in the Preclinical and Clinical Phase of Drug Development. Current drug metabolism. 2021;22(11):838-57.

- A. F. Aubry, L. J. Christopher, J. Wang, M. Zhu, G. Tirucherai, M. E. Arnold. Reflecting on a decade of metabolite screening and monitoring. Bioanalysis. 2014;6(5):651-64.

- M. Zhu, D. Zhang, H. Zhang, W. C. Shyu. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Biopharmaceutics & drug disposition. 2009;30(4):163-84.

- Z. Zhang, M. Zhu, W. Tang. Metabolite identification and profiling in drug design: current practice and future directions. Current pharmaceutical design. 2009;15(19):2220-35.

- X. Wei, and M. Zhu. Chapter 7. Regulatory considerations of drug metabolism and drug interaction studies. In “Drug Metabolism in Drug Design and Development: Basic Concepts and Practice”. Editors, Zhang, M. Zhu, W. G. Humphreys. John Wiley & Sons, October 2007.

- A. Fura, Y. Z. Shu, M. Zhu, R. L. Hanson, V. Roongta, W. G. Humphreys. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. Journal of medicinal chemistry. 2004;47(18):4339-51.